Cargando…

Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX?

Detalles Bibliográficos
Autores principales:	Fernandes, Gustavo dos Santos, Pereira, Allan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615872/ https://www.ncbi.nlm.nih.gov/pubmed/31354965 http://dx.doi.org/10.1136/esmoopen-2019-000537

Ejemplares similares

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis
por: Zhang, Beilei, et al.
Publicado: (2021)

Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?
por: Maman, Yossi, et al.
Publicado: (2023)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
por: Kim, Jinkook, et al.
Publicado: (2021)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

Pancreatic cancer and FOLFIRINOX: a new era and new questions
por: Marsh, Robert De W, et al.
Publicado: (2015)

A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer
por: Chen, Kuei-Ting, et al.
Publicado: (2023)

Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy
por: Yamada, Yunami, et al.
Publicado: (2018)

The self-assessment trap: can we all be better than average?
por: Norel, Raquel, et al.
Publicado: (2011)

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014)

FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study
por: Rombouts, SJ, et al.
Publicado: (2016)

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
por: Sawada, Masashi, et al.
Publicado: (2020)

Treatment of Pulmonary Hypertension: Is Triple Therapy Necessarily Better than Monotherapy?
por: Sun, Xishi, et al.
Publicado: (2021)

The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2019)

SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy
por: Racu, Marie-Lucie, et al.
Publicado: (2023)

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges
por: Yang, Feng, et al.
Publicado: (2019)

Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer
por: Chen, Zhiliang, et al.
Publicado: (2021)

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
por: Stein, Stacey M, et al.
Publicado: (2016)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
por: Cho, In Rae, et al.
Publicado: (2020)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

Cancer of Unknown Primary With Presumptive Pancreatic Cancer Treated With FOLFIRINOX
por: Inoue, Naonori, et al.
Publicado: (2021)

Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer
por: Jung, Jae Hyup, et al.
Publicado: (2022)

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy
por: Guion-Dusserre, Jean-Florian, et al.
Publicado: (2016)

Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
por: Williet, Nicolas, et al.
Publicado: (2019)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
por: Qi, Changsong, et al.
Publicado: (2023)

A phase 1 study of first-in-class agent CPI-613 in combination with FOLFIRINOX for metastatic pancreatic cancer
por: Alistar, Angela, et al.
Publicado: (2017)

FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II Studies
por: Thibodeau, Stephane, et al.
Publicado: (2018)

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
por: Di Costanzo, Francesco, et al.
Publicado: (2023)

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience
por: Chllamma, Muralidharan K, et al.
Publicado: (2016)

Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer
por: Kays, Joshua K., et al.
Publicado: (2018)

Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI
por: Nikolaou, Christos, et al.
Publicado: (2015)

Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma
por: Lellouche, Lisa, et al.
Publicado: (2023)

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study
por: Suker, Mustafa, et al.
Publicado: (2018)

Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer
por: Li, Xujia, et al.
Publicado: (2023)

Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial
por: Lambert, Aurélien, et al.
Publicado: (2017)

Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment
por: Jung, Jae Hyup, et al.
Publicado: (2020)

Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
por: Lee, Yoon Suk, et al.
Publicado: (2021)

A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Sasaki, Mitsuhito, et al.
Publicado: (2021)

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
por: Fukahori, Masaru, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_be9088ggjr5joda2g2vsj7lme6